Lasmiditan Succinate
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Lasmiditan Succinate |
| DrugBank ID | DB11732 |
| Brand Names (EU) | Rayvow |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.94% |
Approved Indication (EMA)
RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | migraine disorder | 99.94% | DL |
| 2 | migraine with brainstem aura | 99.92% | DL |
| 3 | migraine with or without aura, susceptibility to | 99.61% | DL |
| 4 | atrophoderma vermiculata | 99.59% | DL |
| 5 | ulerythema ophryogenesis | 99.46% | DL |
| 6 | sciatic neuropathy | 96.51% | DL |
| 7 | monogenic obesity | 88.83% | DL |
| 8 | obesity disorder | 87.57% | DL |
| 9 | obsolete hypertelorism (disease) | 86.37% | DL |
| 10 | hypervitaminosis | 86.15% | DL |
| 11 | amenorrhea (disease) | 84.73% | DL |
| 12 | frontorhiny | 82.74% | DL |
| 13 | proximal 16p11.2 microdeletion syndrome | 80.01% | DL |
| 14 | lesion of sciatic nerve | 79.64% | DL |
| 15 | anxiety | 75.04% | DL |
| 16 | tendinitis | 73.69% | DL |
| 17 | myositis fibrosa | 71.50% | DL |
| 18 | idiopathic granulomatous myositis | 71.50% | DL |
| 19 | trigeminal autonomic cephalalgia | 68.27% | DL |
| 20 | headache disorder | 66.06% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.